The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...
Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are implicated in tumour growth, tumour resistance to ...
With two cell therapies approved and three more in its pipeline, Bristol Myers Squibb is working to beef up its manufacturing capabilities for the complex, personalized, one-and-done medicines. On ...
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...
Mitochondrial apoptosis pathways are controlled by Bcl-2 proteins, enclosing antiapoptotic (e.g. Bcl-2 and Mcl-1), proapoptotic multidomain (Bax and Bak) and proapoptotic BH3-only proteins (e.g. Bid).
As a top cancer executive at Bristol Myers Squibb, Kristen Hege oversaw development of the cell therapy that would become Abecma, the first FDA- approved treatment for multiple myeloma that’s made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results